Hong Liu-Seifert

Summary

Affiliation: Eli Lilly and Company
Country: USA

Publications

  1. pmc Sexual dysfunction in patients with schizophrenia treated with conventional antipsychotics or risperidone
    Hong Liu-Seifert
    Lilly Research Laboratories, Eli Lilly and Company, Lilly Corporate Center, Indianapolis, IN, USA
    Neuropsychiatr Dis Treat 5:47-54. 2009
  2. pmc Patient perception of medication benefit and early treatment discontinuation in a 1-year study of patients with schizophrenia
    Hong Liu-Seifert
    Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, IN, USA
    Patient Prefer Adherence 1:9-17. 2007
  3. pmc Patient perspectives on antipsychotic treatments and their association with clinical outcomes
    Hong Liu-Seifert
    Lilly Research Laboratories, Indianapolis, IN, USA
    Patient Prefer Adherence 4:369-77. 2010
  4. pmc A closer look at the baseline-observation-carried-forward (BOCF)
    Hong Liu-Seifert
    Lilly Research Laboratories, Indianapolis, IN, USA
    Patient Prefer Adherence 4:11-6. 2010
  5. pmc Predictors of premature discontinuation of treatment in multiple disease states
    Eric Nantz
    Department of Statistics, Western Michigan University, Kalamazoo, MI, USA
    Patient Prefer Adherence 3:31-43. 2009
  6. pmc Discontinuation of treatment of schizophrenic patients is driven by poor symptom response: a pooled post-hoc analysis of four atypical antipsychotic drugs
    Hong Liu-Seifert
    Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, Indiana, USA
    BMC Med 3:21. 2005
  7. doi request reprint Factors associated with adherence to treatment with olanzapine and other atypical antipsychotic medications in patients with schizophrenia
    Hong Liu-Seifert
    Lilly Research Laboratories, Eli Lilly and Company, Lilly Corporate Center, Indianapolis, IN 46285, USA
    Compr Psychiatry 53:107-15. 2012
  8. pmc Change in level of productivity in the treatment of schizophrenia with olanzapine or other antipsychotics
    Hong Liu-Seifert
    Lilly Research Laboratories, Indianapolis, Indiana, USA
    BMC Psychiatry 11:87. 2011
  9. ncbi request reprint Differential rates of treatment discontinuation in clinical trials as a measure of treatment effectiveness for olanzapine and comparator atypical antipsychotics for schizophrenia
    Bruce J Kinon
    Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, IN 46285, USA
    J Clin Psychopharmacol 26:632-7. 2006
  10. ncbi request reprint Randomized, double-blind 6-month comparison of olanzapine and quetiapine in patients with schizophrenia or schizoaffective disorder with prominent negative symptoms and poor functioning
    Bruce J Kinon
    Lilly Research Laboratories, Eli Lilly and Company, Lilly Corporate Center, Indianapolis, IN 46285, USA
    J Clin Psychopharmacol 26:453-61. 2006

Detail Information

Publications22

  1. pmc Sexual dysfunction in patients with schizophrenia treated with conventional antipsychotics or risperidone
    Hong Liu-Seifert
    Lilly Research Laboratories, Eli Lilly and Company, Lilly Corporate Center, Indianapolis, IN, USA
    Neuropsychiatr Dis Treat 5:47-54. 2009
    ..To better understand sexual dysfunction in patients with schizophrenia and its associations with prolactin and reproductive hormones...
  2. pmc Patient perception of medication benefit and early treatment discontinuation in a 1-year study of patients with schizophrenia
    Hong Liu-Seifert
    Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, IN, USA
    Patient Prefer Adherence 1:9-17. 2007
    ..Associations of patient beliefs about medication with clinical psychopathology and their life satisfaction were also assessed...
  3. pmc Patient perspectives on antipsychotic treatments and their association with clinical outcomes
    Hong Liu-Seifert
    Lilly Research Laboratories, Indianapolis, IN, USA
    Patient Prefer Adherence 4:369-77. 2010
    ..Furthermore, olanzapine may be associated with more positive treatment attitudes. These findings may contribute to a better understanding of reasons for treatment adherence from patients' own perspectives...
  4. pmc A closer look at the baseline-observation-carried-forward (BOCF)
    Hong Liu-Seifert
    Lilly Research Laboratories, Indianapolis, IN, USA
    Patient Prefer Adherence 4:11-6. 2010
    ..We examined modifications of this approach, taking into consideration treatment-related and nontreatment-related reasons for discontinuation...
  5. pmc Predictors of premature discontinuation of treatment in multiple disease states
    Eric Nantz
    Department of Statistics, Western Michigan University, Kalamazoo, MI, USA
    Patient Prefer Adherence 3:31-43. 2009
    ..Systematic analysis of data from clinical trials across several disease states was performed to identify predictors of premature discontinuation during clinical interventions...
  6. pmc Discontinuation of treatment of schizophrenic patients is driven by poor symptom response: a pooled post-hoc analysis of four atypical antipsychotic drugs
    Hong Liu-Seifert
    Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, Indiana, USA
    BMC Med 3:21. 2005
    ..Stopping antipsychotic treatment can interrupt improvement and exacerbate the illness. The reasons for discontinuing treatment during controlled clinical trials were analyzed to explore this phenomenon...
  7. doi request reprint Factors associated with adherence to treatment with olanzapine and other atypical antipsychotic medications in patients with schizophrenia
    Hong Liu-Seifert
    Lilly Research Laboratories, Eli Lilly and Company, Lilly Corporate Center, Indianapolis, IN 46285, USA
    Compr Psychiatry 53:107-15. 2012
    ....
  8. pmc Change in level of productivity in the treatment of schizophrenia with olanzapine or other antipsychotics
    Hong Liu-Seifert
    Lilly Research Laboratories, Indianapolis, Indiana, USA
    BMC Psychiatry 11:87. 2011
    ..We also assessed the links between productivity level and other clinical outcomes...
  9. ncbi request reprint Differential rates of treatment discontinuation in clinical trials as a measure of treatment effectiveness for olanzapine and comparator atypical antipsychotics for schizophrenia
    Bruce J Kinon
    Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, IN 46285, USA
    J Clin Psychopharmacol 26:632-7. 2006
    ....
  10. ncbi request reprint Randomized, double-blind 6-month comparison of olanzapine and quetiapine in patients with schizophrenia or schizoaffective disorder with prominent negative symptoms and poor functioning
    Bruce J Kinon
    Lilly Research Laboratories, Eli Lilly and Company, Lilly Corporate Center, Indianapolis, IN 46285, USA
    J Clin Psychopharmacol 26:453-61. 2006
    ..Greater improvement in positive symptoms and a greater study completion rate may hold relevance to enhanced functional outcomes observed after OLZ therapy...
  11. doi request reprint Standard and higher dose of olanzapine in patients with schizophrenia or schizoaffective disorder: a randomized, double-blind, fixed-dose study
    Bruce J Kinon
    Eli Lilly and Company, Lilly Corporate Center, Drop Code 4133, Indianapolis, IN 46285, USA
    J Clin Psychopharmacol 28:392-400. 2008
    ....
  12. doi request reprint A double-blind, randomized, placebo-controlled study of the efficacy and safety of duloxetine for the treatment of chronic pain due to osteoarthritis of the knee
    Amy S Chappell
    Lilly Research Laboratories, Indianapolis, Indiana 46285, USA
    Pain Pract 11:33-41. 2011
    ..To evaluate the efficacy and safety of duloxetine in the treatment of chronic pain due to osteoarthritis of the knee...
  13. doi request reprint Bone loss associated with hyperprolactinemia in patients with schizophrenia
    Bruce J Kinon
    Lilly Corporate Center, Eli Lilly and Company, Indianapolis, IN
    Clin Schizophr Relat Psychoses 7:115-23. 2013
    ..The objective of this study was to determine the prevalence of low BMD in patients with schizophrenia treated with conventional antipsychotics or risperidone and to evaluate any potential relationship with treatment...
  14. ncbi request reprint Olanzapine treatment for tardive dyskinesia in schizophrenia patients: a prospective clinical trial with patients randomized to blinded dose reduction periods
    Bruce J Kinon
    Lilly Research Laboratories, Eli Lilly and Company, Lilly Corporate Center, Drop Code 4133, Indianapolis, IN 46285, USA
    Prog Neuropsychopharmacol Biol Psychiatry 28:985-96. 2004
    ..The aim of this 8-month study was to determine if olanzapine treatment could lead to a significant and persistent reduction in preexisting TD...
  15. ncbi request reprint Improvement in hyperprolactinemia and reproductive comorbidities in patients with schizophrenia switched from conventional antipsychotics or risperidone to olanzapine
    Bruce J Kinon
    Lilly Research Laboratories, Eli Lilly and Company, Lilly Corporate Center, Drop Code 4133, Indianapolis, IN 46285, USA
    Psychoneuroendocrinology 31:577-88. 2006
    ..Olanzapine treatment may offer sustained reduction in serum prolactin and improvement in sexual and reproductive comorbid symptoms in patients with schizophrenia who have treatment-emergent hyperprolactinemia...
  16. doi request reprint Efficacy and safety of duloxetine in patients with chronic low back pain
    Vladimir Skljarevski
    Lilly Research Laboratories, Indianapolis, IN, USA
    Spine (Phila Pa 1976) 35:E578-85. 2010
    ..This was a randomized, double-blind, placebo-controlled clinical trial...
  17. ncbi request reprint Longitudinal effect of olanzapine on fasting serum lipids: a randomized, prospective, 4-month study
    Bruce J Kinon
    Lilly Research Laboratories, Eli Lilly and Company, Lilly Corporate Center, Drop Code 4133, Indianapolis, IN 46285, USA
    Ann N Y Acad Sci 1032:295-6. 2004
    ....
  18. ncbi request reprint Osteopenia associated with increased prolactin and aging in psychiatric patients treated with prolactin-elevating antipsychotics
    Hong Liu-Seifert
    Lilly Research Laboratories, Eli Lilly and Company, Lilly Corporate Center, Drop Code 4133, Indianapolis, Indiana 46285, USA
    Ann N Y Acad Sci 1032:297-8. 2004
    ..Identified risk factors appear to be age and hyperprolactinemia for both females and males...
  19. ncbi request reprint Sexual dysfunction associated with neuroleptic-induced hyperprolactinemia improves with reduction in prolactin levels
    Jonna Ahl
    Lilly Research Laboratories, Eli Lilly and Company, Lilly Corporate Center, Drop Code 4133, Indianapolis, IN 46285, USA
    Ann N Y Acad Sci 1032:289-90. 2004
    ..Our findings indicate that sexual function improved with euprolactinemia in patients switched from treatment with prolactin-elevating antipsychotics to olanzapine...
  20. ncbi request reprint All-cause treatment discontinuation in schizophrenia during treatment with olanzapine relative to other antipsychotics: an integrated analysis
    Charles M Beasley
    Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, IN 46285, USA
    J Clin Psychopharmacol 27:252-8. 2007
    ..This integrated analysis compared the likelihood of discontinuation from olanzapine treatment versus other antipsychotics among patients with schizophrenia...
  21. doi request reprint Duloxetine, a centrally acting analgesic, in the treatment of patients with osteoarthritis knee pain: a 13-week, randomized, placebo-controlled trial
    Amy S Chappell
    Lilly Research Laboratories, Indianapolis, IN, USA
    Pain 146:253-60. 2009
    ..Adverse-event rates did not differ significantly between treatment groups (49.5% for duloxetine 60-120 mg/day, and 40.8% for placebo)...
  22. ncbi request reprint Association of acute symptoms and compliance attitude in noncompliant patients with schizophrenia
    Hong Liu-Seifert
    J Clin Psychopharmacol 27:392-4. 2007